Glucocorticoid insensitivity at the hypoxic blood-brain barrier can be reversed by inhibition of the proteasome

Stroke

Volumn 42, Issue 4, 2011, Pages 1081-1089

  Kleinschnitz, Christoph ^a   Blecharz, Kinga ^a   Kahles, Timo ^b   Schwarz, Tobias ^a   Kraft, Peter ^a   Göbel, Kerstin ^c   Meuth, Sven G ^c   Burek, Malgorzata ^a   Thum, Thomas ^d   Stoll, Guido ^a   Förster, Carola ^a  

^a UNIVERSITY OF WÜRZBURG   (Germany)

^b WEILL CORNELL MEDICAL COLLEGE   (United States)

^c UNIVERSITY OF MÜNSTER   (Germany)

^d HANNOVER MEDICAL SCHOOL   (Germany)

Author keywords

blood brain barrier; nuclear receptor; proteasome; steroids; stroke

Indexed keywords

BORTEZOMIB; DEXAMETHASONE; GLUCOCORTICOID; GLUCOCORTICOID RECEPTOR; GLUCOSE; METHYLPREDNISOLONE; OXYGEN; PROTEASOME; PROTEASOME INHIBITOR;

ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; BLOOD BRAIN BARRIER; BRAIN EDEMA; BRAIN HYPOXIA; BRAIN INFARCTION; BRAIN VASCULAR RESISTANCE; CONTROLLED STUDY; DRUG ACTIVITY; DRUG SENSITIVITY; ENZYME INHIBITION; FUNCTIONAL STATUS; IN VITRO STUDY; IN VIVO STUDY; MICROVASCULAR ENDOTHELIAL CELL; MIDDLE CEREBRAL ARTERY OCCLUSION; MONOTHERAPY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STROKE;

ANIMALS; BLOOD-BRAIN BARRIER; CELL HYPOXIA; CELL LINE, TRANSFORMED; DISEASE MODELS, ANIMAL; DRUG RESISTANCE, MULTIPLE; ENDOTHELIAL CELLS; GLUCOCORTICOIDS; HYPOXIA-ISCHEMIA, BRAIN; MICE; ORGAN CULTURE TECHNIQUES; PROTEASE INHIBITORS; PROTEASOME ENDOPEPTIDASE COMPLEX; STROKE; TREATMENT OUTCOME;

EID: 79954904198     PISSN: 00392499     EISSN: None     Source Type: Journal    
DOI: 10.1161/STROKEAHA.110.592238     Document Type: Article

References (39)

1. De Reuck J, Vandekerckhove T, Bosma G, De Meulemeester K, Van Landegem W, De Waele J, Tack E, De Koninck J. Steroid treatment in acute ischaemic stroke. A comparative retrospective study of 556 cases. Eur Neurol. 1988;28:70-72. (Pubitemid 18092790)
2. Kumar N, Jain S, Maheshwari MC. Role of dexamethasone in the outcome from acute stroke. J Assoc Physicians India. 1989;37:315-317.
3. Norris JW. Steroids may have a role in stroke therapy. Stroke. 2004;35: 228-229. (Pubitemid 38057623)
4. Norris JW, Hachinski VC. High dose steroid treatment in cerebral infarction. BMJ (Clin Res Ed). 1986;292:21-23. (Pubitemid 16175878)
5. Poungvarin N. Steroids have no role in stroke therapy. Stroke. 2004;35: 229-230. (Pubitemid 38057624)
6. Bardutzky J, Schwab S. Antiedema therapy in ischemic stroke. Stroke. 2007;38:3084-3094. (Pubitemid 350035708)
7. Beato M. Gene regulation by steroid hormones. Cell. 1989;56:335-344. (Pubitemid 19052651)
8. Harke N, Leers J, Kietz S, Drenckhahn D, Forster C. Identification of a distal glucocorticoid responsive element in the occludin gene coding region. Mol Cell Endocrinol. 2008;295:39-47.
9. Wallace AD, Cidlowski JA. Proteasome-mediated glucocorticoid receptor degradation restricts transcriptional signaling by glucocorticoids. J Biol Chem. 2001;276:42714-42721.
10. Kurebayashi J, Otsuki T, Moriya T, Sonoo H. Hypoxia reduces hormone responsiveness of human breast cancer cells. Jpn J Cancer Res. 2001;92: 1093-1101. (Pubitemid 33041178)
11. Stoner M, Saville B, Wormke M, Dean D, Burghardt R, Safe S. Hypoxia induces proteasome-dependent degradation of estrogen receptor alpha in zr-75 breast cancer cells. Mol Endocrinol. 2002;16:2231-2242. (Pubitemid 35155536)
12. Meller R. The role of the ubiquitin proteasome system in ischemia and ischemic tolerance. Neuroscientist. 2009;15:243-260.
13. Dirnagl U. Bench to bedside: the quest for quality in experimental stroke research. J Cereb Blood Flow Metab. 2006;26:1465-1478. (Pubitemid 44809076)
14. Kleinschnitz C, Schwab N, Kraft P, Hagedorn I, Dreykluft A, Schwarz T, Austinat M, Nieswandt B, Wiendl H, Stoll G. Early detrimental T-cell effects in experimental cerebral ischemia are neither related to adaptive immunity nor thrombus formation. Blood. 2010;115:3835-3842.
15. Kleinschnitz C, Stoll G, Bendszus M, Schuh K, Pauer HU, Burfeind P, Renne C, Gailani D, Nieswandt B, Renne T. Targeting coagulation factor XII provides protection from pathological thrombosis in cerebral ischemia without interfering with hemostasis. J Exp Med. 2006;203:513-518.
16. Austinat M, Braeuninger S, Pesquero JB, Brede M, Bader M, Stoll G, Renne T, Kleinschnitz C. Blockade of bradykinin receptor B1 but not bradykinin receptor B2 provides protection from cerebral infarction and brain edema. Stroke. 2009;40:285-293.
17. Bederson JB, Pitts LH, Tsuji M, Nishimura MC, Davis RL, Bartkowski H. Rat middle cerebral artery occlusion: evaluation of the model and development of a neurologic examination. Stroke. 1986;17:472-476. (Pubitemid 16085691)
18. Forster C, Silwedel C, Golenhofen N, Burek M, Kietz S, Mankertz J, Drenckhahn D. Occludin as direct target for glucocorticoid-induced improvement of blood-brain barrier properties in a murine in vitro system. J Physiol. 2005;565:475-486. (Pubitemid 40879596)
19. Decker T, Lohmann-Matthes ML. A quick and simple method for the quantitation of lactate dehydrogenase release in measurements of cellular cytotoxicity and tumor necrosis factor (TNF) activity. J Immunol Methods. 1988;115:61-69.
20. Gobel K, Melzer N, Herrmann AM, Schuhmann MK, Bittner S, Ip CW, Hunig T, Meuth SG, Wiendl H. Collateral neuronal apoptosis in CNS gray matter during an oligodendrocyte-directed CD8(+) T cell attack. Glia. 2010;58:469-480.
21. Kim H, Yoon SC, Lee TY, Jeong D. Discriminative cytotoxicity assessment based on various cellular damages. Toxicol Lett. 2009;184: 13-17.
22. Benore-Parsons M, Liebman J, Wennogle LP. Binding of glucocorticoid receptors to model DNA response elements. J Cell Biochem. 1991;47: 330-336.
23. Narasimhan P, Liu J, Song YS, Massengale JL, Chan PH. VEGF stimulates the ERK 1/2 signaling pathway and apoptosis in cerebral endothelial cells after ischemic conditions. Stroke. 2009;40:1467-1473.
24. Forster C. Tight junctions and the modulation of barrier function in disease. Histochem Cell Biol. 2008;130:55-70.
25. Zhou J, Cidlowski JA. The human glucocorticoid receptor: one gene, multiple proteins and diverse responses. Steroids. 2005;70:407-417. (Pubitemid 40616039)
26. Forster C, Waschke J, Burek M, Leers J, Drenckhahn D. Glucocorticoid effects on mouse microvascular endothelial barrier permeability are brain specific. J Physiol. 2006;573:413-425. (Pubitemid 43871056)
27. Leonard MO, Godson C, Brady HR, Taylor CT. Potentiation of glucocorticoid activity in hypoxia through induction of the glucocorticoid receptor. J Immunol. 2005;174:2250-2257. (Pubitemid 40223972)
28. Rubin LL, Staddon JM. The cell biology of the blood-brain barrier. Annu Rev Neurosci. 1999;22:11-28. (Pubitemid 29144879)
29. D'Atri F, Citi S. Molecular complexity of vertebrate tight junctions. Mol Membr Biol. 2002;19:103-112. (Pubitemid 34753314)
30. Strbian D, Durukan A, Pitkonen M, Marinkovic I, Tatlisumak E, Pedrono E, Abo-Ramadan U, Tatlisumak T. The blood-brain barrier is continuously open for several weeks following transient focal cerebral ischemia. Neuroscience. 2008;153:175-181.
31. Wardlaw JM, Doubal F, Armitage P, Chappell F, Carpenter T, Munoz Maniega S, Farrall A, Sudlow C, Dennis M, Dhillon B. Lacunar stroke is associated with diffuse blood-brain barrier dysfunction. Ann Neurol. 2009;65:194-202.
32. Koto T, Takubo K, Ishida S, Shinoda H, Inoue M, Tsubota K, Okada Y, Ikeda E. Hypoxia disrupts the barrier function of neural blood vessels through changes in the expression of claudin-5 in endothelial cells. Am J Pathol. 2007;170:1389-1397. (Pubitemid 47339345)
33. Kago T, Takagi N, Date I, Takenaga Y, Takagi K, Takeo S. Cerebral ischemia enhances tyrosine phosphorylation of occludin in brain capillaries. Biochem Biophys Res Commun. 2006;339:1197-1203. (Pubitemid 41790589)
34. Chen F, Ohashi N, Li W, Eckman C, Nguyen JH. Disruptions of occludin and claudin-5 in brain endothelial cells in vitro and in brains of mice with acute liver failure. Hepatology. 2009;50:1914-1923.
35. Garside H, Waters C, Berry A, Rice L, Ardley HC, White A, Robinson PA, Ray D. UbcH7 interacts with the glucocorticoid receptor and mediates receptor autoregulation. J Endocrinol. 2006;190:621-629. (Pubitemid 44560237)
36. Tronche F, Kellendonk C, Reichardt HM, Schutz G. Genetic dissection of glucocorticoid receptor function in mice. Curr Opin Genet Dev. 1998;8: 532-538. (Pubitemid 28477355)
37. Lee BH, Wen TC, Rogido M, Sola A. Glucocorticoid receptor expression in the cortex of the neonatal rat brain with and without focal cerebral ischemia. Neonatology. 2007;91:12-19. (Pubitemid 46150651)
38. Williams AJ, Dave JR, Tortella FC. Neuroprotection with the proteasome inhibitor mln519 in focal ischemic brain injury: relation to nuclear factor kappaB (NF-kappaB), inflammatory gene expression, and leukocyte infiltration. Neurochem Int. 2006;49:106-112. (Pubitemid 44172911)
39. Zhang L, Zhang ZG, Buller B, Jiang J, Jiang Y, Zhao D, Liu X, Morris D, Chopp M. Combination treatment with VELCADE and low-dose tissue plasminogen activator provides potent neuroprotection in aged rats after embolic focal ischemia. Stroke. 2010;41:1001-1007.